Clovis Oncology secures EC approval for Rubraca’s new indication in ovarian cancer treatment
In a major win for Clovis Oncology, the European Commission (EC) has granted approval for an expanded indication for its cancer drug, Rubraca (rucaparib). This approval allows the PARP inhibitor to be used as a maintenance treatment for adult women with relapsed ovarian cancer, offering new hope for patients battling this challenging disease. The decision […]